Roche Holding AG (0QQ6.L)

CHF 291.8

(1.46%)

Market Cap (In CHF)

220.67 Billion

Revenue (In CHF)

58.71 Billion

Net Income (In CHF)

11.49 Billion

Avg. Volume

9031.00

Currency
CHF
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
236.0-317.4
PE
18.02
EPS
16.197
Beta Value
0.145
ISIN
CH0012032113
CUSIP
-
CIK
-
Shares
755349681.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Dr. Thomas Schinecker
Employee Count
-
Website
https://www.roche.com
Ipo Date
2014-03-07
Details
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.